02 March 2021: Clinical Research
The Role of Human Leukocyte Antigen-DR in Regulatory T Cells in Patients with Virus-Induced Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Lin Zhang AE , Xiuhong Nie AE* , Zhiming Luo BC , Bing Wei D , Guojie Teng FDOI: 10.12659/MSM.928051
Med Sci Monit 2021; 27:e928051
Table 2 Flow cytometry analysis of frequencies of T cell subsets in the virus group, nonvirus group, stable COPD group, and healthy smoking group.
| Health smokers (n=20) | Stable COPD (n= 20) | Virus AECOPD (n=32) | Non-virus AECOPD (n=31) | P | ||
|---|---|---|---|---|---|---|
| CD3+ | 65.2±10.6 | 60.8±13.8 | 54.2±16.2 | 54.0±20.0 | 0.250 | |
| GOLD II | 65.4±11.2 | 61.5±14.3 | 57.9±22.2 | |||
| GOLD III–IV | 56.2±15.9 | 48.0±17.2 | 51.4±20.1 | |||
| CD4+ | 57.5±8.3 | 56.3±6.6 | 54.9±11.1 | 58.5±8.2 | 0.715 | |
| GOLD II | 54.1±6.1 | 51.7±1.8 | 55.7±5.2 | |||
| GOLD III–IV | 59.0±6.7 | 57.2±15.1 | 60.4±9.7 | |||
| CD4+Naive | 22.4±8.9 | 22.8±7.9 | 18.0±9.3 | 25.1±13.5 | 0.572 | |
| GOLD II | 24.1±17.8 | 22.3±12.1 | 21.7±8.1 | |||
| GOLD III–IV | 20.8±6.9 | 14.7±5.7 | 29.1±16.2 | |||
| CD4+Tcm | 41.1±4.4 | 39.3±4.9 | 42.0±10.1 | 41.7±10.0 | 0.641 | |
| GOLD II | 40.7±4.0 | 45.9±10.7 | 45.9±10.5 | |||
| GOLD III–IV | 36.8±5.6 | 39.1±10.0 | 38.9±9.4 | |||
| CD4+Tem | 31.9±8.9 | 32.7±9.0 | 37.8±14.4 | 28.4±10.7 | 0.330 | |
| GOLD II | 34.6±9.5 | 29.6±10.4 | 28.3±4.2 | |||
| GOLD III–IV | 30.5±8.9 | 43.9±14.9 | 28.4±13.9 | |||
| CD4+End | 3.2 (1.8–7.4) | 3.5 (2.1–6.4) | 2.4 (1.9–2.7) | 3.3 (2.1–5.9) | 0.408 | |
| GOLD II | 2.2 (1.2–7.0) | 2.5 (0.5–2.8) | 3.9 (1.1–7.6) | |||
| GOLD III–IV | 4.2 (2.9–5.9) | 2.2 (1.9–2.6) | 3.3 (2.3–4.3) | |||
| CD4+HLA-DR+ | 1.6 (1.0–2.3) | 1.3 (1.1–2.1) | 2.2 (1.9–2.5) | 4.2 (2.9–8.5) | 0.015 | |
| GOLD II | 1.6 (0.9–2.2) | 2.4 (1.9–2.6) | 4.9 (2.4–9.6) | |||
| GOLD III–IV | 1.2 (1.1–2.0) | 2.1 (1.7–2.3) | 4.2 (3.2–8.7) | |||
| CD4+Treg | 5.8 (5.3–6.8) | 4.8 (3.2–5.1) | 12.8 (8.8–14.0) | 13.1 (12.0–16.4) | 0.001 | |
| GOLD II | 5.1 (4.6–5.5) | 13.3 (12.1–14.8) | 12.9 (11.2–15.6) | |||
| GOLD III–IV | 3.9 (3.0–5.1) | 9.5 (6.7–13.1) | 13.1 (12.5–19.4) | |||
| CD4+Treg-HLA-DR+ | 0.9 (0.5–1.7) | 1.1 (0.6–1.9) | 1.1 (0.9–1.7) | 3.6 (1.1–4.7) | 0.011 | |
| GOLD II | 1.1 (0.8–1.4) | 1.5 (0.8–1.7) | 3.2 (1.3–4.4) | |||
| GOLD III–IV | 0.9 (0.3–2.1) | 1.0 (0.9–1.5) | 3.6 (1.2–6.9) | |||
| CD4+Treg-HLA-DR− | 4.7 (4.2–5.1) | 3.1 (2.4–4.8) | 10.7 (7.7–12.3) | 10.6 (7.0–13.9) | 0.001 | |
| GOLD II | 3.0 (2.3–4.8) | 11.9 (10.7–13.4) | 10.1 (7.7–12.9) | |||
| GOLD III–IV | 3.4 (2.3–5.0) | 8.5 (5.7–11.5) | 11.8 (5.6–17.8) | |||
| CD8+ | 29.7±8.7 | 28.8±7.2 | 37.4±10.9 | 28.2±7.9 | 0.179 | |
| GOLD II | 31.6±8.4 | 40.9±3.6 | 30.6±7.5 | |||
| GOLD III–IV | 25.3±3.8 | 34.8±14.5 | 26.6±8.4 | |||
| CD8+Naive | 9.2 (6.3–11.4) | 10.1 (6.1–15.0) | 11.8 (4.0–23.1) | 14.0 (9.7–20.3) | 0.354 | |
| GOLD II | 6.4 (5.7–20.7) | 12.8 (6.0–24.3) | 15.4 (9.8–19.6) | |||
| GOLD III–IV | 11.9 (5.0–14.3) | 5.9 (2.1–19.3) | 13.9 (7.8–23.3) | |||
| CD8+Tcm | 10.8±4.7 | 12.5±4.5 | 13.9±7.8 | 14.7±8.3 | 0.574 | |
| GOLD II | 13.3±4.0 | 16.9±4.7 | 16.1±4.8 | |||
| GOLD III–IV | 11.1±5.6 | 11.6±9.5 | 13.9±10.4 | |||
| CD8+Tem | 42.1±14.2 | 40.4±12.9 | 44.5±14.4 | 40.5±17.7 | 0.691 | |
| GOLD II | 36.0±12.1 | 35.3±16.7 | 37.3±17.8 | |||
| GOLD III–IV | 45.6±13.2 | 51.5±8.7 | 42.5±19.0 | |||
| CD8+End | 35.5±14.9 | 30.4±13.9 | 29.3±14.2 | 29.9±16.2 | 0.799 | |
| GOLD II | 31.2±10.6 | 31.2±17.7 | 31.6±20.8 | |||
| GOLD III–IV | 29.5±18.6 | 27.8±13.6 | 28.7±15.4 | |||
| CD8+HLA-DR+ | 1.0 (0.8–1.7) | 1.2 (0.7–1.9) | 2.2 (1.8–2.4) | 1.6 (1.1–2.4) | 0.284 | |
| GOLD II | 1.5 (1.1–2.8) | 2.0 (1.8–2.2) | 1.5 (0.8–2.3) | |||
| GOLD III–IV | 0.9 (0.5–1.7) | 2.3 (1.0–2.4) | 1.6 (1.2–2.5) | |||
| CD4+:CD8+ratio | 2.1±0.7 | 1.8±0.6 | 1.7±1.0 | 2.3±1.0 | 0.449 | |
| GOLD II | 1.7±0.5 | 1.3±0.2 | 1.9±0.4 | |||
| GOLD III–IV | 2.0±1.2 | 2.0±1.3 | 2.5±1.3 | |||
| COPD – chronic obstructive pulmonary disease; End – end-stage T cell (CD45ROCD62L); naïve T cell (CD45ROCD62L); Tcm – central memory T cell (CD45ROCD62L); Tem – effector memory T cell (CD45ROCD62L); Treg – regulatory T cell (CD4CD25CD127). | ||||||